Last reviewed · How we verify
MV-CHIK low dose
At a glance
| Generic name | MV-CHIK low dose |
|---|---|
| Also known as | vaccine against Chikungunya |
| Sponsor | Themis Bioscience GmbH |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine (PHASE2)
- Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005) (PHASE2)
- Phase I Trial of Measles Vectored Chikungungya Vaccine (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MV-CHIK low dose CI brief — competitive landscape report
- MV-CHIK low dose updates RSS · CI watch RSS
- Themis Bioscience GmbH portfolio CI